FRM
ACRS icon

Fox Run Management’s Aclaris Therapeutics ACRS Stock Holding History

Fox Run Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,350
Closed -$258K – 623
2022
Q4 		$258K Buy
16,350
+1,422
+10% +$22.9K 0.1% 394
2022
Q3 		$235K Buy
+14,928
New +$235K 0.09% 435
2022
Q1 		– Sell
-19,368
Closed -$282K – 479
2021
Q4 		$282K Buy
+19,368
New +$293K 0.17% 248
2018
Q2 		– Sell
-10,900
Closed -$191K – 633
2018
Q1 		$191K Buy
+10,900
New +$231K 0.05% 640

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Fox Run Management's ACRS Position: Q1 2023 in Review

Fox Run Management sold out of Aclaris Therapeutics (ACRS) in Q1 2023, closing a stake of 16,350 shares — an estimated $258K sold.

Fox Run Management first reported a position in ACRS in Q1 2018 and held it in 4 quarters. The position peaked at $282K in Q4 2021. 148 funds tracked by Wall St. Rank hold ACRS as of Q1 2023.

  • Fox Run Management reported no remaining Aclaris Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Fox Run Management sold 16,350 Aclaris Therapeutics shares in Q1 2023, an estimated $258K.
  • Fox Run Management first reported a position in Aclaris Therapeutics in Q1 2018 and held it in 4 quarters.
  • Fox Run Management's Aclaris Therapeutics position peaked at $282K in Q4 2021.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2023.

Based on Fox Run Management's 13F filing for Q1 2023, filed 12 May 2023.